Danaher's (DHR) Masimo said Monday it received US Food and Drug Administration clearance for an opioid-induced respiratory depression detection capability integrated into the Radius VSM wearable continuous patient monitor.

The company said the feature, enabled by Masimo's next-generation smartSET pulse oximetry sensor platform, uses pattern-recognition technology to analyze continuous physiological data and help clinicians identify early signs of respiratory compromise in hospital patients receiving opioid therapy.

The feature includes visual alarms that alert clinicians to rising OIRD risk and can relay alarms to remote and centralized monitoring stations, it added.